COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis

A Jena, D James, AK Singh, U Dutta… - Clinical …, 2022 - Elsevier
Background And Aims The serological responses after severe acute respiratory syndrome
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …

Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States

SB Coburn, E Humes, R Lang, C Stewart… - JAMA network …, 2022 - jamanetwork.com
Importance Recommendations for additional doses of COVID-19 vaccines for people with
HIV (PWH) are restricted to those with advanced disease or unsuppressed HIV viral load …

[HTML][HTML] Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article

J Barrière, M Carles, C Audigier-Valette, D Re… - European Journal of …, 2022 - Elsevier
Taking into account higher risk of severe coronavirus disease 2019 or death among patients
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

T Starkey, MC Ionescu, M Tilby, M Little, E Burke… - Scientific Reports, 2023 - nature.com
Patients with cancer are at increased risk of hospitalisation and mortality following severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV …

[HTML][HTML] Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis

AS Mai, ARYB Lee, RYK Tay, L Shapiro… - European Journal of …, 2022 - Elsevier
Importance Patients with cancer have an increased risk of severe disease and mortality from
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …

Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis

A Sakuraba, A Luna, D Micic - Journal of hematology & oncology, 2022 - Springer
Purpose Patients with cancer have an increased risk of coronavirus disease 2019 (COVID-
19) and an attenuated responses to various vaccines. This meta-analysis aims to assess the …

Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review

Y Al Hajji, H Taylor, T Starkey, LYW Lee… - British Journal of …, 2022 - nature.com
Background Patients living with cancer are at a significantly increased risk of morbidity and
mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV …

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity

T Shree, V Shankar, JJK Lohmeyer, DK Czerwinski… - Blood cancer …, 2022 - AACR
To obtain a deeper understanding of poor responses to COVID-19 vaccination in patients
with lymphoma, we assessed blocking antibodies, total anti-spike IgG, and spike-specific …

[HTML][HTML] Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events–a retrospective …

MJ Mair, JM Berger, M Mitterer, M Gansterer… - European Journal of …, 2022 - Elsevier
Background Due to potentially immune-esca** virus variants and waning immunity, a third
SARS-CoV-2 vaccination dose is increasingly recommended. However, data in patients with …